atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
Schizophrenia is a psychiatric disorder characterized by altered thinking and emotional patterns, hallucinations, false or irrational beliefs (i.e., delusions), cognitive deficits, and disorganized speech.
Bipolar disorder BD, on the other hand, is marked by extreme mood swings, ranging between periods of…
New joint research program combines UCSF’s advanced clinical and research teams with GE HealthCare’s technical and engineering expertise to develop solutions that directly impact patient care.
Read full article here.
Attendees
Sponsors and Exhibitors
Contact us